Indivior Pharmaceuticals, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Indivior Pharmaceuticals, Inc. (INDV) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-02-26
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $0.00.
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-12-31 was $0.00.
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-09-30 was $1.00M.
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $1.00M, a 99.38% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $162.00M.
- Indivior Pharmaceuticals, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.00M derived: sum of 2 quarters · filed 2026-02-26 | $1.00M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.00M 10-Q · filed 2025-10-30 | $1.00M 10-Q · filed 2025-10-30 | ||
| 2023-12-31 | $162.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |